Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 16, 2017. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Price: $39.01 per ADS.
- Total Volume: 10,064.708 ADSs aggregated across all reported transactions.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document exclusively details increases in notional interest in ADSs resulting from the re-investment of dividends paid on January 12, 2017, under the Company's 2009 Performance Share Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of specific equity transactions.
Important Facts for Investors
- Transaction Nature: All reported transactions were automatic dividend re-investments, not open-market purchases or sales.
- Transaction Date: All transactions occurred on January 12, 2017.
- Executives Involved:
- Dr. M M Slaoui (Chairman, Global Vaccines) and Dr. K Slaoui (PCA).
- Mr. N Hirons (SVP, Global Ethics & Compliance).
- Mr. B McNamara (CEO, GSK Consumer Healthcare).
- Mr. D E Troy (SVP & General Counsel).
- Share Price: The ADS price at the time of transaction was $39.01.